SEC Filing Analysis: PLUS THERAPEUTICS, INC. (PSTV)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Financial Officer, Andrew Sims, executed a small open-market purchase of common stock valued at $10,200.
• Market Impact: The transaction is not material in size and is unlikely to have a noticeable impact on the stock.

Company Information

Field	Value
Company	PLUS THERAPEUTICS, INC.
Ticker Symbol	PSTV
CIK	0001095981
Industry	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Insider Information

Field	Value
Name	Sims Andrew John Hugh MacIntyre
CIK	0001802687
Title/Position	Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-04
Transaction Code	P (Open market purchase)
Security Type	Common Stock
Shares Involved	20,000
Price Per Share	$0.51
Total Value	$10,200
Shares Owned After	68,138
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$10,200
% of Market Cap	0.02%
Shares Transacted	20,000
% of Shares Outstanding	0.02%
Post-Transaction Ownership	68,138 shares (0.07% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a nano-cap company with a $50 million market capitalization, this $10,200 transaction is considered minor.
• Ownership Concentration: The purchase increases the CFO's ownership, but their total holding remains a very small fraction (0.07%) of the total shares outstanding.
• Transaction Significance: The transaction represents less than 0.1% of both market capitalization and shares outstanding, placing it in the 'Low' significance category. While it shows some insider confidence, the small scale limits its signaling power.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction size is too small to be considered a strong bullish signal or to materially affect supply and demand for the stock.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction is unlikely to drive any significant change in trading volume.
• Sentiment Indicator: Neutral. The purchase is a routine-sized transaction for an executive and does not strongly indicate a bullish or bearish outlook.

Additional Context

Transaction Notes

• Special Circumstances: The reported price of $0.51 is a weighted average. The shares were acquired in multiple transactions at prices ranging from $0.504 to $0.509, as noted in the filing's footnote.